» Articles » PMID: 38878159

METTL14 is Involved in TNF-α-Induced Inflammation in Colorectal Epithelial Cells Via Autophagy Modulation

Overview
Date 2024 Jun 15
PMID 38878159
Authors
Affiliations
Soon will be listed here.
Abstract

Ulcerative colitis (UC) is a chronic and relapsing inflammatory bowel disease (IBD) characterized by colorectal inflammation. The N6-methyladenosine (m6A) modification of RNA regulates gene expression through the modulation of RNA metabolism, thus influencing various physiological and pathological processes. The aim of this study was to investigate the biological function of m6A methyltransferase METTL14 in colorectal epithelial cell inflammation. Bioinformatics analysis indicated that METTL14 expression was decreased in UC and was associated with disease severity and immune infiltration. We also noted a downregulation of METTL14 expression and a decrease in the total m6A RNA levels in TNF-α-stimulated Caco-2 cells. Moreover, METTL14 knockdown promoted inflammation and inhibited autophagy in TNF-α-stimulated Caco-2 cells, as indicated by the upregulation of NF-κB signaling and pro-inflammatory cytokine expression as well as LC3B protein downregulation. Treatment with the autophagy activator Torin-1 ameliorated the pro-inflammatory effects of METTL14 silencing. Furthermore, METTL14 knockdown significantly reduced the expression of ATG5. ATG5 overexpression could nullify the pro-inflammatory effect of METTL14 knockdown in TNF-α-stimulated Caco-2 cells. Mechanistically, METTL14 knockdown promoted ATG5 mRNA degradation, and luciferase analysis identified ATG5 as a target of m6A modification by METTL14. Taken together, silencing METTL14 promoted inflammation in Caco-2 cells via the downregulation of ATG5. Our findings revealed the importance of the m6A modification in colonic inflammation and autophagy, indicating that targeting METTL14 might be a potential therapeutic strategy for anti-inflammatory treatment in UC.

Citing Articles

Interplay of m6A RNA methylation and gut microbiota in modulating gut injury.

Wang H, Han J, Zhang X Gut Microbes. 2025; 17(1):2467213.

PMID: 39960310 PMC: 11834532. DOI: 10.1080/19490976.2025.2467213.

References
1.
Mbachi C, Attar B, Oyenubi O, Yuchen W, Efesomwan A, Paintsil I . Association between cannabis use and complications related to ulcerative colitis in hospitalized patients: A propensity matched retrospective cohort study. Medicine (Baltimore). 2019; 98(32):e16551. PMC: 6708902. DOI: 10.1097/MD.0000000000016551. View

2.
Li X, Song P, Li J, Tao Y, Li G, Li X . The Disease Burden and Clinical Characteristics of Inflammatory Bowel Disease in the Chinese Population: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2017; 14(3). PMC: 5369074. DOI: 10.3390/ijerph14030238. View

3.
Yang H, Cai R, Kong Z, Chen Y, Cheng C, Qi S . Teasaponin Ameliorates Murine Colitis by Regulating Gut Microbiota and Suppressing the Immune System Response. Front Med (Lausanne). 2020; 7:584369. PMC: 7758452. DOI: 10.3389/fmed.2020.584369. View

4.
Atreya I, Atreya R, Neurath M . NF-kappaB in inflammatory bowel disease. J Intern Med. 2008; 263(6):591-6. DOI: 10.1111/j.1365-2796.2008.01953.x. View

5.
Han J, Li Y, Zhang B, Liu H, Wu M, Zhang X . lncRNA TUG1 regulates ulcerative colitis through miR-142-5p/SOCS1 axis. Microb Pathog. 2020; 143:104139. DOI: 10.1016/j.micpath.2020.104139. View